Reviewing the role of progesterone therapy in endometriosis
- 25 July 2018
- journal article
- review article
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 35 (1) , 10-16
Abstract
Endometriosis is a benign, chronic inflammatory condition characterized by the presence and growth of endometrial implants outside the uterine cavity. The cause of endometriosis is multifactorial. It is due to the diversity of hypothesis and plausibility of hormonal alterations which could play a major role. Evidence has shown that progesterone resistance is a key factor for endometriosis sufferers. Medical therapy can avoid surgical intervention, which may lead to a reduced in ovarian reserve, and its effects of earlier menopause and reduced fecundity. Progesterone receptor isoform has provided new insight as the potential treatment. Progestin, anti-progestin and selective progesterone receptor modulators usage, which target these receptors, could avoid hypo-estrogenic side effects, which can be debilitating. Numerous types of these medications have been used on and off labeled to treat endometriosis with varying success. This review aims to consolidate series of clinical trials using progestins in endometriosis.Keywords
Funding Information
- UKMMC (FFF-2017–045, FRGS/1/2017/SKK08/UKM/01/4)
- UKMMC
This publication has 58 references indexed in Scilit:
- Expression of the gamma 2 chain of laminin-332 in eutopic and ectopic endometrium of patients with endometriosisReproductive Biology and Endocrinology, 2013
- Dienogest increases the progesterone receptor isoform B/A ratio in patients with ovarian endometriosisJournal of Ovarian Research, 2012
- Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosisInternational Journal of Gynecology & Obstetrics, 2012
- Reduced pelvic pain in women with endometriosis: efficacy of long-term dienogest treatmentArchives of Gynecology and Obstetrics, 2011
- Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogueFertility and Sterility, 2011
- Dienogest, a new conservative strategy for extragenital endometriosis: a pilot studyGynecological Endocrinology, 2010
- A dose‐ranging study to determine the efficacy and safety of 1, 2, and 4 mg of dienogest daily for endometriosisInternational Journal of Gynecology & Obstetrics, 2009
- EndometriosisDrugs, 2009
- Effective post-laparoscopic treatment of endometriosis with dydrogesteroneGynecological Endocrinology, 2007
- Changes in quality of life after hormonal treatment of endometriosisActa Obstetricia et Gynecologica Scandinavica, 2001